+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years +
All Genders
ID06887218

Randomized Study Comparing 5-FluorouracilLeucovorin Plus Regorafenib Versus Trifluridine-Tipiracil With Bevacizumab in Metastatic Colorectal Cancer

Led by The Methodist Hospital Research Institute · Updated on 2026-10-07

57

Participants Needed

1

Research Sites

52 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the effectiveness and safety of combining 5-FluorouracilLeucovorin 5FULV with regorafenib for adults with metastatic colorectal cancer who have already tried two prior treatments. This randomized phase II trial compares this combination to a control treatment of trifluridine-tipiracil plus bevacizumab to understand if the new combination is not worse than the current option. The study aims to provide insights in the third-line treatment setting for this advanced cancer. Participants are randomly assigned in a 21 ratio to one of two treatment groups. The experimental group receives 5FULV given intravenously in 2-week cycles along with regorafenib taken orally with dose escalation weekly, following a 3-weeks-on1-week-off schedule, for up to 12 cycles or until disease progression or unacceptable side effects. The control group is given oral trifluridine-tipiracil twice daily on specified days in a 28-day cycle, combined with intravenous bevacizumab on days 1 and 15, repeated until progression, toxicity, or consent withdrawal, also up to 12 cycles. Throughout the study, participants undergo regular assessments to monitor treatment effects and side effects. Researchers measure how long the treatment controls the cancer, progression-free survival, response duration, and safety. Evaluations include clinical exams, laboratory tests, and monitoring for any adverse events. The study duration and follow-up extend up to 18 months to capture these outcomes and ensure participant safety and well-being during and after treatment.

CONDITIONS

Brief Title

5-Fluorouracil/Leucovorin (5FU/LV) in Combination With Regorafenib in Patients With Metastatic Colorectal Cancer

Research Team

S

Safiya Joseph

T

Titilayo Olubajo

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here